Inhibrx Biosciences Inc.

NASDAQ: INBX · Real-Time Price · USD
23.82
-0.12 (-0.50%)
At close: Aug 15, 2025, 10:04 AM

Inhibrx Biosciences Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
200K 1.8M 2.19M 7.13M
Cost of Revenue
2.29M 1.19M 110.19M 2.69M
Gross Profit
-2.08M 609K -107.99M 4.44M
Operating Income
-331.45M -219.22M -129.12M -76.56M
Interest Income
10.94M 11.92M 16.11M 5.22M
Pretax Income
1.69B -239.72M -145.22M -81.77M
Net Income
1.69B -241.36M -145.23M -81.77M
Selling & General & Admin
127.91M 29.38M 21.12M 12.36M
Research & Development
203.74M 190.65M 110.19M 71.44M
Other Expenses
-2.29M -199K -110.19M -71.45M
Operating Expenses
329.36M 219.83M 21.12M 12.34M
Interest Expense
13.49M 31.84M 16.11M 5.22M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
331.65M 221.02M 131.29M 83.69M
Income Tax Expense
2K 3K 3K 2K
Shares Outstanding (Basic)
14.48M 47.13M 40.11M 38.01M
Shares Outstanding (Diluted)
14.48M 47.13M 40.11M 38.01M
EPS (Basic)
116.58 -5.12 -3.62 -2.15
EPS (Diluted)
116.58 -5.12 -3.62 -2.15
EBITDA
1.7B -206.69M -125.82M -75.37M
EBIT
1.7B -207.88M -127.04M -76.56M
Depreciation & Amortization
2.29M 1.19M 1.23M 1.2M